But right now, state employees and people on MassHealth are petrified. All carriers with the Massachusetts Health Connector decided to stop covering GLP-drugs for 2026 strictly for weight loss, and additional GLP-1 cost pressure could come from MassHealth
Clinical evidence shows all approved GLP-1 agents have similar side effect profiles, with nausea, vomiting, and constipation most common during dose escalation
Other online telehealth pharmacies are selling compounded versions of GLP-1 medications, which can be purchased without insurance and are not subject to FDA review and approval
The expression levels of inflammatory mediators, including IL-1, Il-6 and TNF-, in intestinal tissues are also lower (Supplementary Fig
Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats
Ozempic or Wegovy should not be used in individuals with: Pregnancy or breastfeeding Severe gastrointestinal disease History of pancreatitis (requires careful assessment) The UK product information notes that animal studies have shown an increased incidence of thyroid C-cell tumours with semaglutide, though the human relevance of this finding is unknown